share_log

Ironwood Pharmaceuticals Announces Results From Phase 2 Exploratory STARGAZE Trial of Apraglutide For Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease

Moomoo 24/7 ·  Mar 28 07:33
  • First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD.
  • Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study's primary objective.
  • Exploratory secondary efficacy data showed lower GI tract responses maintained through Day 91 in SR GI aGVHD patients treated with apraglutide and standard of care.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment